Microgen – Russian pharmaceutical company.
Federal State Scientific-Industrial Company MICROGEN is the largest company in Russian medical industry that holds leadership in development and production of immunobiological preparations, diagnosticums and drugs.
Consortium MICROGEN was founded in May, 2003 in order to create a competitive enterprise in the field of medical immunobiology that could ensure the implementation of national programs of biological and epidemiological security, development of domestic biotechnological industry in accordance with international standards of drug production and practical application of new and highly effective preparations.
Subsidiaries that were amalgamated within the MICROGEN have a history that is more than a hundred years long. They were created on the basis of Pasteur centers and laboratories that conducted studies in the field of immunobiology.
At present Federal State Scientific-Industrial Company MICROGEN is a modern enterprise that holds leadership position in the domestic pharmaceutical industry. Production output for MICROGEN in the year 2013 was more than US$150m.
The company steadily widens the shipping geography of its immunobiological products: they go to the CIS countries (Kazakhstan, Ukraine, Byelorussia, Uzbekistan, Azerbaijan, Armenia, Georgia), Mexico, Mongolia, Vietnam, India. A number of countries of Africa, South-East Asia and Latin America are conducting talks concerning future cooperation.
MICROGEN Consortium in active cooperation with leading Russian and foreign research centers is working on designing and application to production development of the unique innovations in immunobiology and biotechnology.
In collaboration with leading Russian scientists the company is striving to develop and manufacture new high-quality preparations, modern pharmaceutical forms.
MICROGEN specialists participate in international research projects including WHO programs for eradication of natural smallpox, measles, rubella, tuberculosis, whooping cough, diphtheria, tetanus, avian flu, etc.
At present more than 15 novel preparations are being prepared for commercial production, e.g. new influenza, smallpox and tick-borne encephalitis vaccines, associated DTP vaccine, hepatitis B vaccine, hemophilic infection vaccine, mumps, measles and rubella vaccine, avian flu vaccine, cell-depleted pertussis vaccine, staphylococcal-proteus-pseudomonas aeruginosa vaccine (SPPA-vaccine) and others.
